In this episode we dive into Medipharm Lab's Q1 2020 results which greatly disappointed the market

- What's going on  with LABS? Why did it have such a drop off in revenue?

- How does it compare to Valens?

- Examining their recent $37M financing (good and bad)

- How the slow 2.0 rollout is hurting the extraction industry

- Why 2019 was such a good year for LABS - will it recover?

- How will the extraction landscape look in the next 1-3 years?